Overview
Early-life supplementation with L. rhamnosus GG (LGG) before 27 days of age reduced the risk of beta-cell autoimmunity in genetically at-risk infants, as demonstrated in the TEDDY study (The Environmental Determinants of Diabetes in the Young).
Mechanism
- The neonatal immune system undergoes a critical window of education shaped by early microbial colonizers
- LGG promotes regulatory T-cell differentiation and immune tolerance during this window
- Early establishment of a diverse, Lactobacillus-enriched microbiome reduces the probability of aberrant autoimmune activation against pancreatic beta cells
Clinical Evidence
The TEDDY study — a large prospective cohort following genetically at-risk children — found that probiotic supplementation initiated before 27 days of age was associated with reduced islet autoantibody seroconversion. The timing window was critical: later supplementation did not show the same benefit.
Clinical Considerations
- Timing is essential: Benefit observed only with supplementation before 27 days of age
- Applicable to genetically at-risk infants (HLA-DR3/DR4 carriers)
- Safety profile of LGG in neonates is well established
- Does not replace breastfeeding, which provides complementary immune benefits